Crosstalk relationship between adiponectin receptors, PPAR-γ and α-adrenoceptors in renal vasculature of diabetic WKYs

Eur J Pharmacol. 2022 Feb 15:917:174703. doi: 10.1016/j.ejphar.2021.174703. Epub 2021 Dec 31.

Abstract

Hypoadiponectinemia is associated with renal dysfunctions. Irbesartan and pioglitazone activate Peroxisome proliferator-activated gamma receptor (PPAR-γ) as partial and full agonists. We investigated a crosstalk interaction and synergistic action between adiponectin receptors, PPAR-γ agonists in attenuating renal hemodynamics to adrenergic agonists in diabetic Wistar Kyoto rats (WKY). Streptozotocin (40 mg/kg) was used to induce diabetes, whereas, pioglitazone (10 mg/kg/day), irbesartan (30 mg/kg/day) administered orally for 28 days and adiponectin intraperitoneally (2.5 μg/kg/day) for last 7 days. Metabolic and plasma samples were analyzed on days 0, 8, 21, and 28. During the acute study (day 29), renal vasoconstrictor actions to adrenergic agonists and angiotensin-II were determined. Diabetic WKYs had lower plasma adiponectin, higher creatinine clearance, urinary and fractional sodium excretion but were normalized to a greater extent in pioglitazone and adiponectin combined treatment. Responses to intra-renal administration of adrenergic agonists including noradrenaline (NA), phenylephrine (PE), methoxamine (ME), and angiotensin-II (ANG-II) were larger in diabetic WKY, but significantly blunted with adiponectin treatment in diabetic WKYs to 35-40%, and further reduced by 65-70% in combination with pioglitazone. Attenuation to ANG-II responses in adiponectin and combination with irbesartan was 30-35% and 75-80%, respectively (P < 0.05). Pharmacodynamically, a crosstalk interaction exists between PPAR-γ, adiponectin receptors (adipo R1 & R2), alpha adrenoceptors, and angiotensin-I (ATI) receptors in the renal vasculature of diabetic WKYs. Exogenously administered adiponectin with full PPAR-γ agonist substantially attenuated renal hemodynamics and improved excretory functions, signifying their renoprotective action. Additionally, a degree of synergism exists between adiponectin and pioglitazone to a large extent compared to combination therapy with irbesartan (partial PPAR-γ agonist) in attenuating the renal vascular receptiveness to adrenergic agonists.

Keywords: Adiponectin; Alpha adrenoceptors; Ang-II; Diabetes; PPAR-γ; Wistar kyoto rats.

MeSH terms

  • Adiponectin / metabolism
  • Angiotensin II / pharmacology
  • Animals
  • Biphenyl Compounds* / pharmacology
  • Biphenyl Compounds* / therapeutic use
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Experimental* / metabolism
  • Irbesartan* / pharmacology
  • Kidney* / blood supply
  • Kidney* / drug effects
  • Kidney* / metabolism
  • Male
  • PPAR gamma* / agonists
  • PPAR gamma* / metabolism
  • Pioglitazone* / pharmacology
  • Rats
  • Rats, Inbred WKY*
  • Receptor Cross-Talk / drug effects
  • Receptors, Adiponectin* / agonists
  • Receptors, Adiponectin* / metabolism
  • Receptors, Adrenergic, alpha* / metabolism
  • Tetrazoles / pharmacology
  • Thiazolidinediones / pharmacology
  • Vasoconstriction / drug effects

Substances

  • Adiponectin
  • Angiotensin II
  • Biphenyl Compounds
  • Irbesartan
  • Pioglitazone
  • PPAR gamma
  • Receptors, Adiponectin
  • Receptors, Adrenergic, alpha
  • Tetrazoles
  • Thiazolidinediones
  • adiponectin receptor 1, rat
  • adiponectin receptor 2, rat